The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000557336p
Ethics application status
Help: Ethics application status
Submitted, not yet approved
Date submitted
Help: Date submitted
10/04/2026
Date registered
Help: Date registered
1/05/2026
Date last updated
Help: Date last updated
1/05/2026
Date data sharing statement initially provided
Help: Data sharing statement date
1/05/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
CLEAR-TKR: Chronic biofilm Local Eradication with Anti-biofilm Regime in Total Knee Replacement
Scientific title
A Phase 1b, open-label, single-arm safety study to evaluate safety, tolerability and proof of concept efficacy of BROMAC following single intra-articular administration in patients with chronically supressed Prosthetic Joint Infection following Total Knee Arthroplasty
Additional trial identifiers [1] 316998 0
nil
Universal Trial Number (UTN)
Trial acronym
CLEAR TKR
Related trial records

Health condition
Health condition(s) studied:
Prosthetic Joint Infection 341478 0
Condition category
Condition code
Surgery 337569 337569 0 0
Other surgery
Infection 337570 337570 0 0
Other infectious diseases

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
a single intra-articular injection of 10ml BromAc® (500microq bromelain + 10mg/ml N-acetylcystein) administered by an experienced trained clinician member of the research team using aseptic technique. This will be given without interruption or modification of the patient's standard suppressive antibiotic therapy (continuation of the same dose and antibiotic choice as prescribed by their regular treating Infectious disease physician prior to enrollment).
Intervention code [1] 333752 0
Treatment: Drugs
Description of the comparator or control
No control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 345047 0
Evaluate safety and tolerability, assessed as a composite outcome, of Intra-articular BromAc® injection in chronically supressed Prosthetic joint infections of the Knee in combination with standard of care therapy
Timepoint [1] 345047 0
24hours, 48hours, 14 days, 42 days, 90days post injection
Secondary outcome [1] 460301 0
Systemic exposure pharmacokinetic profile of BromAc
Timepoint [1] 460301 0
baseline, 24 hours, 48 hours post injection
Secondary outcome [2] 460303 0
Change of blood inflammatory markers from BromAc®
Timepoint [2] 460303 0
baseline, 24,48 hours post injection
Secondary outcome [3] 461121 0
Change in Patient Reported Outcome Measurements of symptoms from BromAc®
Timepoint [3] 461121 0
Baseline (1-7days prior to injection), Day 2,14,42,90 post injection

Eligibility
Key inclusion criteria
1. Male or female patients aged over 18 years, inclusive, at time of screening
2. Patients who are able to provide informed consent, geographically stable and able to comply with the required follow up visits, testing schedule and medical regimen
3. Patients with a confirmed diagnosis of a Prosthetic Joint Infection of the knee (as defined by European Bone & Joint Infection Society - EBJIS - criteria); who are on lifelong suppressive antibiotic therapy.
4. Patients with a life expectancy of at least 1 year
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
1. Patients who are currently planned for further revision surgery of the affected knee prosthesis or ongoing active changes to standard of care treatment regardless of cause
2. Patients with mycobacterium or fungal etiology of Prosthetic Joint Infection (PJI) at time of screening
3. Patients who have active substance dependence or abuse that, in the investigator’s opinion, might interfere with patient safety and/or compliance with the protocol
4. Patients with malignant disease who have received immunosuppressive therapy, radiation therapy or chemotherapy within the last 3 months
5. Patients with known immunodeficiency (eg. Splenectomy, sickle cell anaemia, human immunodeficiency virus, recent bone marrow or other transplant
6. Female patients who are pregnant or lactating
7. Patients with allergy to the study drug or any excipients or components of the study drug
8. Patients who participated in any clinical trial of an investigational drug or device within 30 days or 5 half-lives, whichever is longer, prior to study drug administration

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 1 / Phase 2
Type of endpoint/s
Safety
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
ACT
Recruitment hospital [1] 29392 0
The Canberra Hospital - Garran
Recruitment postcode(s) [1] 45712 0
2605 - Garran

Funding & Sponsors
Funding source category [1] 321595 0
Government body
Name [1] 321595 0
ACT Health
Country [1] 321595 0
Australia
Primary sponsor type
Government body
Name
ACT Health
Address
Country
Australia
Secondary sponsor category [1] 324403 0
None
Name [1] 324403 0
Address [1] 324403 0
Country [1] 324403 0

Ethics approval
Ethics application status
Submitted, not yet approved
Ethics committee name [1] 320122 0
ACT Health Human Research Ethics Committee
Ethics committee address [1] 320122 0
Ethics committee country [1] 320122 0
Australia
Date submitted for ethics approval [1] 320122 0
09/04/2026
Approval date [1] 320122 0
Ethics approval number [1] 320122 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 149506 0
Dr Sam MIschewski
Address 149506 0
Trauma and Orthopaedic Research Unit, The Canberra Hospital, Yamba Dr, Garran ACT 2605
Country 149506 0
Australia
Phone 149506 0
+61 413785595
Fax 149506 0
Email 149506 0
Contact person for public queries
Name 149507 0
Sam MIschewski
Address 149507 0
Trauma and Orthopaedic Research Unit, The Canberra Hospital, Yamba Dr, Garran ACT 2605
Country 149507 0
Australia
Phone 149507 0
+61 251240000
Fax 149507 0
Email 149507 0
Contact person for scientific queries
Name 149508 0
Sam Mischewski
Address 149508 0
Trauma and Orthopaedic Research Unit, The Canberra Hospital, Yamba Dr, Garran ACT 2605
Country 149508 0
Australia
Phone 149508 0
+61 413785595
Fax 149508 0
Email 149508 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.